MRI Monopoly? How BMC’s Tender Sparked a Procurement Storm

In India’s financial capital, civic hospitals carry the promise of affordable healthcare. And yet, this promise now lies in tension with a newly surfacing alarming issue. Mumbai’s civic body may be structuring MRI machine procurement tenders to favour a single international brand, effectively limiting fair competition and risking public funds.

The Brihanmumbai Municipal Corporation (BMC) recently floated tenders for high-end 3-Tesla MRI units across its four teaching hospitals. Instead of multiple bidders stepping forward, the process repeatedly attracted bids from only one firm named international conglomerate Siemens. Experts and insiders suggest that technical conditions in the tender for example, demanding a 64-channel configuration, a high gradient strength range, and 3-Tesla capacity, effectively exclude offerings from prominent vendors like Philips (typically 32 channels) and GE Healthcare (offering alternate features). In addition, the tender’s requirement that magnets be manufactured only in the USA, Europe, or Japan disqualified Chinese companies like United Imaging.

While the BMC's technical committee argues that the specific specifications reflect medical needs for world-class imaging, critics point out that these precise technical thresholds may be less about medical necessity and more about exclusion. The result: a process that appears to presuppose the winner before bids even arrive. Its observed that the procurement guidelines seem custom-written for Siemens hardware undermining the notion of a competitive and open tender.

This situation is not new for the BMC. Past public scrutiny has revealed similar procurement anomalies. In one previous purchase of two MRI machines, the civic body paid nearly ₹16.5 crore, when independent sourcing indicated the same equipment could have been obtained for under ₹9.5 crore. Allegations then also pointed to lack of transparency and opaque pricing, prompting calls for an overhaul of procurement policy. Critics suggested those machines were single-source deals dressed as tenders.

Fast forward to now: Mumbai’s public MRI demand is high. Each tertiary hospital handles a backlog where patients wait months, unable to access critical diagnostic services. For instance, a single functional MRI at KEM Hospital generates an embarrassingly long queue forcing patients to either defer scans or go to private centres charging sometimes double the civic nominal rate of ₹2,500 per scan. No wonder procurement delays and bid rejections directly impact clinical care and revenue estimates for civic hospitals.

Imagine a pregnant woman or an elderly patient requiring urgent neuro-imaging but facing long turns and sporadic machine availability. Hospitals lose not just revenue but also credibility. Every delay compromises not only diagnostics but also trust. That’s the real cost, not only financial, but human.

This tender bias reveals two urgent needs: first, a transparent procurement framework with clear, medical-justified, and inclusive specifications. BMC had earlier committed to publishing all tender clauses openly and instituting integrity bonds for bidders, acknowledging the need for reform. If implemented properly, such measures could restore fairness and rebuild vendor confidence.

Second, there must be regular review and validation of technical standards through independent committees including clinicians, radiologists, technical experts, and procurement auditors so that specifications reflect true clinical objectives, not vendor advantages. It's also suggested that if only one brand can meet a tender’s criteria, procuring the unit as proprietary equipment would eliminate the pretense of competitive bidding altogether.

Medical colleges and hospital systems affiliated with the civic hospitals must also engage. Waiting times and capacity strains spread into medical training and outpatient care. Delays in MRI access force faculty to refer students elsewhere, disrupt diagnostic learning, and burden patients financially. The tender controversy, therefore, is a real barrier to equitable healthcare education and service.

Constructive solutions are possible. BMC could revise the tender using Quality and Cost-Based System (QCBS) guidelines, where technical and commercial scores are balanced, and status as lowest-price bidder (L1) does not automatically win out over quality. QCBS is already in use in Indian procurement when quality and clinical requirements matter. It helps prevent cost bias or specification bias from determining the outcome.

Also, BMC can appoint a civilian procurement oversight board with independent experts to pre-review specifications before tenders are floated. At least three competing vendors with comparable machines should be qualified to bid. Frequent extensions to tenders due to lack of bidders are red flags and not administrative flexibility. A failure to attract bids repeatedly indicates that tender design is at fault.

In districts and tertiary hospitals, clinicians should monitor the backlog of MRI requests. If capacity constraints exceed a few weeks, standard prioritization protocols may need revision, and interim access must be ensured via crowd-sourced agreements or low-rate partnerships with outside diagnostic labs at BMC rates. Patients consistently suffering access issues cannot wait for procurement cycles to complete.

All stakeholders including state health authorities, hospital medical boards, civic procurement units must also ensure price parity. In previous procurements, BMC paid lakhs more than local market quotations, with little public justification.  Now, as in earlier cases, there's reason to suspect institutional opacity rather than medical necessity.

This is a moment to demand equitable procurement governance. A model state must not procure infrastructure that is out of reach for its public from private providers. Patients must benefit from economies of scale and negotiation, not silently subsidise inflated tender processes.

Ultimately, an MRI tender is about diagnostic life support. It should reflect medical humility, procedural integrity, and a commitment to public interest. When tender conditions are so restrictive that no vendor but the favoured one can bid, patients lose.

The presentation of clinical equipment specifications may seem technical, but its consequences are clinical too: diagnosing stroke late, delaying cancer detection, postponing neurological scans. This affects lives. A tender is more than paperwork, it is a lifeline. If that lifeline is narrowed artificially, India’s most vulnerable patients risk being cut off.

Transparency is not charity, it is public policy. Integrity in procurement is not optional, it is moral imperative. For Mumbai’s civic hospitals to fulfill their promise, they must first free their tenders from bias, reopen bidding to qualified competitors, and deliver diagnostics not just on paper, but in practice.

Because in a city that defines itself by public spirit, every tender must honour public trust. And in healthcare, trust is the most critical scanner of all.

#PublicHealth #CivicHospitals #HealthcareForAll #RightToDiagnostics #IntegrityInHealth #PublicHealth #MumbaiHealthCrisis #PublicTrust #healthvoice